Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Royalty income	$ 10,965	$ 10,295	$ 6,608
License revenue	690	59,081	1,955
Other revenue	43	53	113
Total revenue	11,698	69,429	8,676
Operating expenses:
Research and development	42,589	37,569	28,196
General and administrative	24,909	23,356	18,184
Change in contingent consideration liability	2,600	(4,600)	1,600
Total operating expenses	70,098	56,325	47,980
Operating (loss) income	(58,400)	13,104	(39,304)
Other (expense) income:
Interest (expense) income, net	(4,285)	(527)	52
Total other (expense) income	(4,285)	(527)	52
(Loss) income before income tax (expense) benefit	(62,685)	12,577	(39,252)
Income tax benefit (expense)	11,672	(1,844)	133
Net (loss) income	(51,013)	10,733	(39,119)
Net loss attributable to noncontrolling interests		(73)	(7)
Net (loss) income attributable to Progenics	$ (51,013)	$ 10,806	$ (39,112)
Net (loss) income per share attributable to Progenics - basic (in dollars per share)	$ (0.73)	$ 0.15	$ (0.56)
Weighted-average shares - basic (in shares)	70,284	70,003	69,716
Net (loss) income per share attributable to Progenics - diluted (in dollars per share)	$ (0.73)	$ 0.15	$ (0.56)
Weighted-average shares - diluted (in shares)	70,284	70,155	69,716